Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Lorazepam | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Lorazepam | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Lorazepam | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | | Lorazepam | hsa00500 | Starch and sucrose metabolism | 2.33E-05 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Lorazepam | hsa00730 | Thiamine metabolism | 1.07E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Lorazepam | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Lorazepam | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Lorazepam | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Lorazepam | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | Lorazepam | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | Lorazepam | hsa03013 | RNA transport | 4.49E-02 | 5 | P62826, Q9UBU9, P63279, P68104, Q14232 | RAN, NXF1, UBE2I, EEF1A1, EIF2B1 | More | | Lorazepam | hsa03020 | RNA polymerase | 6.08E-05 | 4 | P30876, P24928, P62487, Q9Y535 | POLR2B, POLR2A, POLR2G, POLR3H | More | | Lorazepam | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Lorazepam | hsa03030 | DNA replication | 5.00E-02 | 1 | P27694 | RPA1 | More | | Lorazepam | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | | Lorazepam | hsa04020 | Calcium signaling pathway | 4.83E-02 | 4 | Q08828, P0DP23, P05141, P51828 | ADCY1, CALM1, SLC25A5, ADCY7 | More | | Lorazepam | hsa04022 | cGMP-PKG signaling pathway | 4.38E-03 | 6 | P18848, P31751, Q08828, P51828, P05141, P0DP23 | ATF4, AKT2, ADCY1, ADCY7, SLC25A5, CALM1 | More | | Lorazepam | hsa04024 | cAMP signaling pathway | 4.18E-03 | 7 | P63092, Q08828, P51828, P31751, P26678, P0DP23, P61586 | GNAS, ADCY1, ADCY7, AKT2, PLN, CALM1, RHOA | More | | Lorazepam | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.79E-03 | 7 | Q8NHW4, P09341, P19875, P25024, P25025, Q13651, P14784 | CCL4L2, CXCL1, CXCL2, CXCR1, CXCR2, IL10RA, IL2RB | More | | Lorazepam | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Lorazepam | hsa04064 | NF-kappa B signaling pathway | 8.24E-07 | 20 | P10415, O00463, P14778, P01584, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, Q13315, P63279, P24522, Q8NHW4, P09341, P19875, Q06643, Q9NQC7 | BCL2, TRAF5, IL1R1, IL1B, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, ATM, UBE2I, GADD45A, CCL4L2, CXCL1, CXCL2, LTB, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.766 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.713 | P06737 | PYGL | Glycogen phosphorylase, liver form | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.924 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.717 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P01584 | IL1B | Interleukin-1 beta | 0.735 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.723 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.783 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.967 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.701 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q8WV28 | BLNK | B-cell linker protein | -0.706 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13315 | ATM | Serine-protein kinase ATM | 0.723 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.739 | P06737 | PYGL | Glycogen phosphorylase, liver form | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.822 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.734 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09341 | CXCL1 | Growth-regulated alpha protein | 0.74 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.789 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | Q13547 | HDAC1 | Histone deacetylase 1 | Q06643 | LTB | Lymphotoxin-beta | 0.74 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.753 |
| Lorazepam | hsa04070 | Phosphatidylinositol signaling system | 9.86E-03 | 4 | P0DP23, O14986, Q16760, P48426 | CALM1, PIP5K1B, DGKD, PIP4K2A | More | | Lorazepam | hsa04071 | Sphingolipid signaling pathway | 8.39E-04 | 8 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | Lorazepam | hsa04072 | Phospholipase D signaling pathway | 5.40E-05 | 13 | P31751, P42338, P61586, P43657, P25024, P25025, P19174, O14986, Q15438, P63092, Q08828, P51828, Q16760 | AKT2, PIK3CB, RHOA, P2RY5, CXCR1, CXCR2, PLCG1, PIP5K1B, PSCD1, GNAS, ADCY1, ADCY7, DGKD | More | | Lorazepam | hsa04080 | Neuroactive ligand-receptor interaction | 9.01E-04 | 10 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581, P07550, P35318 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1, ADRB2, ADM | More | | Lorazepam | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | | Lorazepam | hsa04114 | Oocyte meiosis | 1.35E-02 | 5 | P0DP23, Q08828, P51828, Q13362, Q14738 | CALM1, ADCY1, ADCY7, PPP2R5C, PPP2R5D | More | | Lorazepam | hsa04120 | Ubiquitin mediated proteolysis | 3.43E-06 | 8 | Q9UBT2, Q14145, Q13042, Q13191, P62837, Q15751, Q14669, Q7Z6Z7 | SAE2, KEAP1, CDC16, CBLB, UBE2D2, HERC1, TRIP12, HUWE1 | More | | Lorazepam | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | Lorazepam | hsa04140 | Autophagy - animal | 1.92E-03 | 9 | P31751, Q7L523, O75460, P22694, Q14643, P10415, Q04759, Q96GC9, Q8TEV9 | AKT2, RRAGA, ERN1, PRKACB, ITPR1, BCL2, PRKCQ, TMEM49, SMCR8 | More | | Lorazepam | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | | Lorazepam | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | Lorazepam | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Lorazepam | hsa04211 | Longevity regulating pathway | 1.88E-02 | 4 | P31751, Q08828, P51828, P18848 | AKT2, ADCY1, ADCY7, ATF4 | More | | Lorazepam | hsa04213 | Longevity regulating pathway - multiple species | 4.29E-03 | 7 | P31751, P42338, Q9Y4H2, Q08828, P51828, P11142, Q13547 | AKT2, PIK3CB, IRS2, ADCY1, ADCY7, HSPA8, HDAC1 | More | | Lorazepam | hsa04217 | Necroptosis | 4.24E-05 | 10 | P01375, P48023, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q13557 | TNF, FASLG, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D | More | | Lorazepam | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.98E-04 | 7 | Q08828, P51828, P31751, P18848, Q13362, Q14738, P0DP23 | ADCY1, ADCY7, AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | | Lorazepam | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | | Lorazepam | hsa04340 | Hedgehog signaling pathway | 1.05E-03 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Lorazepam | hsa04371 | Apelin signaling pathway | 3.94E-02 | 4 | P31751, Q08828, P51828, P0DP23 | AKT2, ADCY1, ADCY7, CALM1 | More | | Lorazepam | hsa04380 | Osteoclast differentiation | 5.27E-04 | 10 | Q9NQC7, Q9UQC2, Q16539, P23458, P31751, P01584, P14778, O75015, P01375, Q8N149 | CYLD, GAB2, MAPK14, JAK1, AKT2, IL1B, IL1R1, FCGR3B, TNF, LILRA2 | More | | Lorazepam | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | | Lorazepam | hsa04514 | Cell adhesion molecules | 1.22E-02 | 2 | P23229, P30511 | ITGA6, HLA-F | More | | Lorazepam | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | | Lorazepam | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | | Lorazepam | hsa04613 | Neutrophil extracellular trap formation | 4.72E-04 | 15 | O60603, P05164, P08246, Q9UM07, P04908, Q93077, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Lorazepam | hsa04620 | Toll-like receptor signaling pathway | 2.54E-03 | 3 | P01584, P31751, Q8NHW4 | IL1B, AKT2, CCL4L2 | More | | Lorazepam | hsa04621 | NOD-like receptor signaling pathway | 5.21E-03 | 12 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, P01375, P09341, P59665, P59666, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, TNF, CXCL1, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Lorazepam | hsa04623 | Cytosolic DNA-sensing pathway | 2.21E-04 | 3 | P01584, Q9Y535, Q8NHW4 | IL1B, POLR3H, CCL4L2 | More | | Lorazepam | hsa04625 | C-type lectin receptor signaling pathway | 1.14E-03 | 8 | Q9ULY5, P01584, Q9NQC7, P20749, P01375, P31751, P0DP23, Q16539 | CLEC4E, IL1B, CYLD, BCL3, TNF, AKT2, CALM1, MAPK14 | More | | Lorazepam | hsa04630 | JAK-STAT signaling pathway | 4.54E-02 | 3 | P31751, P23458, Q13651 | AKT2, JAK1, IL10RA | More | | Lorazepam | hsa04640 | Hematopoietic cell lineage | 2.18E-03 | 9 | P14778, P27930, P11215, P25063, P07766, P01732, P01730, P06127, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD4, CD5, CD7 | More | | Lorazepam | hsa04650 | Natural killer cell mediated cytotoxicity | 4.11E-05 | 12 | P19174, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, P26715 | PLCG1, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | Lorazepam | hsa04657 | IL-17 signaling pathway | 6.02E-05 | 9 | P07900, O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Lorazepam | hsa04658 | Th1 and Th2 cell differentiation | 6.24E-10 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P42226, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, STAT6, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.736 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.742 | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.884 |
| Lorazepam | hsa04659 | Th17 cell differentiation | 4.35E-07 | 13 | Q04759, Q16539, P19174, P06239, P42226, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, PLCG1, LCK, STAT6, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.909 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 |
| Lorazepam | hsa04660 | T cell receptor signaling pathway | 5.17E-06 | 16 | P01375, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Lorazepam | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | | Lorazepam | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | | Lorazepam | hsa04713 | Circadian entrainment | 5.44E-03 | 5 | P0DP23, P62873, Q08828, P51828, P63092 | CALM1, GNB1, ADCY1, ADCY7, GNAS | More | | Lorazepam | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Lorazepam | hsa04720 | Long-term potentiation | 4.54E-02 | 3 | P0DP23, P18848, Q08828 | CALM1, ATF4, ADCY1 | More | | Lorazepam | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Lorazepam | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | | Lorazepam | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | Lorazepam | hsa04725 | Cholinergic synapse | 1.39E-02 | 4 | Q08828, P51828, P18848, P31751 | ADCY1, ADCY7, ATF4, AKT2 | More | | Lorazepam | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | Lorazepam | hsa04728 | Dopaminergic synapse | 7.83E-03 | 5 | P31751, P18848, Q13362, Q14738, P0DP23 | AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | | Lorazepam | hsa04730 | Long-term depression | 5.00E-02 | 1 | Q14344 | GNA13 | More | | Lorazepam | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.03E-04 | 9 | P14778, P01584, Q08828, P51828, P19174, P42338, P24723, Q04759, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PLCG1, PIK3CB, PRKCH, PRKCQ, CALM1 | More | | Lorazepam | hsa04810 | Regulation of actin cytoskeleton | 2.68E-02 | 2 | P23229, Q14344 | ITGA6, GNA13 | More | | Lorazepam | hsa04911 | Insulin secretion | 2.40E-02 | 3 | Q08828, P51828, P18848 | ADCY1, ADCY7, ATF4 | More | | Lorazepam | hsa04912 | GnRH signaling pathway | 1.39E-02 | 4 | Q08828, P51828, P18848, P0DP23 | ADCY1, ADCY7, ATF4, CALM1 | More | | Lorazepam | hsa04915 | Estrogen signaling pathway | 2.13E-02 | 5 | P18848, Q08828, P51828, P31751, P0DP23 | ATF4, ADCY1, ADCY7, AKT2, CALM1 | More | | Lorazepam | hsa04916 | Melanogenesis | 2.40E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | | Lorazepam | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Lorazepam | hsa04923 | Regulation of lipolysis in adipocytes | 2.89E-04 | 6 | Q08828, P51828, P07550, P42338, Q9Y4H2, P31751 | ADCY1, ADCY7, ADRB2, PIK3CB, IRS2, AKT2 | More | | Lorazepam | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Lorazepam | hsa04925 | Aldosterone synthesis and secretion | 9.86E-03 | 4 | P18848, Q08828, P51828, P0DP23 | ATF4, ADCY1, ADCY7, CALM1 | More | | Lorazepam | hsa04926 | Relaxin signaling pathway | 2.46E-02 | 4 | P31751, P18848, Q08828, P51828 | AKT2, ATF4, ADCY1, ADCY7 | More | | Lorazepam | hsa04927 | Cortisol synthesis and secretion | 1.59E-02 | 3 | P18848, Q08828, P51828 | ATF4, ADCY1, ADCY7 | More | | Lorazepam | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | Lorazepam | hsa04932 | Non-alcoholic fatty liver disease | 1.89E-06 | 12 | P31751, P01375, P49841, P18848, P48023, O75460, P01584, P13073, O15239, Q16718, O95298, O14521 | AKT2, TNF, GSK3B, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA1, NDUFA5, NDUFC2, SDHD | More | | Lorazepam | hsa04934 | Cushing syndrome | 4.54E-02 | 3 | P18848, Q08828, P51828 | ATF4, ADCY1, ADCY7 | More | | Lorazepam | hsa04935 | Growth hormone synthesis, secretion and action | 1.88E-02 | 4 | Q08828, P51828, P18848, P31751 | ADCY1, ADCY7, ATF4, AKT2 | More | | Lorazepam | hsa04940 | Type I diabetes mellitus | 6.87E-04 | 2 | P48023, P01375 | FASLG, TNF | More | | Lorazepam | hsa04970 | Salivary secretion | 1.59E-02 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | | Lorazepam | hsa04971 | Gastric acid secretion | 2.54E-03 | 4 | Q08828, P51828, P15311, P0DP23 | ADCY1, ADCY7, VIL2, CALM1 | More | | Lorazepam | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | | Lorazepam | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Lorazepam | hsa04976 | Bile secretion | 9.77E-04 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | Lorazepam | hsa05010 | Alzheimer disease | 4.94E-03 | 9 | O95298, Q00535, O75460, P0DP23, P01584, P18848, P31751, P05141, P28070 | NDUFC2, CDK5, ERN1, CALM1, IL1B, ATF4, AKT2, SLC25A5, PSMB4 | More | | Lorazepam | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | | Lorazepam | hsa05016 | Huntington disease | 2.14E-03 | 9 | O15239, O95298, P13073, P24928, P30876, P62487, P05141, O75460, P28070 | NDUFA1, NDUFC2, COX4I1, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4 | More | | Lorazepam | hsa05017 | Spinocerebellar ataxia | 3.94E-02 | 4 | O75460, P31751, P28070, P05141 | ERN1, AKT2, PSMB4, SLC25A5 | More | | Lorazepam | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | | Lorazepam | hsa05022 | Pathways of neurodegeneration - multiple diseases | 6.87E-05 | 18 | P49841, O15239, Q16718, O95298, O14521, P13073, Q8TEV9, O75460, P18848, Q13561, P05141, Q16539, Q00535, P01584, Q08752, P0DP23, Q13557, P28070 | GSK3B, NDUFA1, NDUFA5, NDUFC2, SDHD, COX4I1, SMCR8, ERN1, ATF4, DCTN2, SLC25A5, MAPK14, CDK5, IL1B, PPID, CALM1, CAMK2D, PSMB4 | More | | Lorazepam | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | | Lorazepam | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Lorazepam | hsa05134 | Legionellosis | 6.38E-04 | 6 | P01584, P11215, P68104, P11142, P09341, P19875 | IL1B, ITGAM, EEF1A1, HSPA8, CXCL1, CXCL2 | More | | Lorazepam | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | | Lorazepam | hsa05143 | African trypanosomiasis | 1.51E-03 | 2 | P01375, P48023 | TNF, FASLG | More | | Lorazepam | hsa05144 | Malaria | 1.44E-02 | 4 | P60033, O60603, P35443, P26718 | CD81, TLR2, THBS4, KLRK1 | More | | Lorazepam | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | | Lorazepam | hsa05150 | Staphylococcus aureus infection | 3.62E-03 | 8 | P21730, P21462, O75015, P13765, Q16581, P59665, P59666, P12838 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Lorazepam | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Lorazepam | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | Lorazepam | hsa05163 | Human cytomegalovirus infection | 1.30E-07 | 21 | P31751, P01375, P30511, P62873, P0DP23, Q14344, P61586, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, P18848, P63092, O00463, P61769 | AKT2, TNF, HLA-F, GNB1, CALM1, GNA13, RHOA, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, ATF4, GNAS, TRAF5, B2M | More | | Lorazepam | hsa05164 | Influenza A | 4.49E-02 | 5 | P31751, P01584, P23458, P05141, Q9UBU9 | AKT2, IL1B, JAK1, SLC25A5, NXF1 | More | | Lorazepam | hsa05166 | Human T-cell leukemia virus 1 infection | 3.90E-02 | 7 | P23458, P05141, P62826, Q08828, P51828, P18848, P31751 | JAK1, SLC25A5, RAN, ADCY1, ADCY7, ATF4, AKT2 | More | | Lorazepam | hsa05169 | Epstein-Barr virus infection | 5.92E-03 | 12 | P13765, Q13547, O00463, P16070, P10415, Q16539, P24522, Q8WV28, P01375, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, CD44, BCL2, MAPK14, GADD45A, BLNK, TNF, TLR2, CD3G, CD247 | More | | Lorazepam | hsa05171 | Coronavirus disease - COVID-19 | 3.15E-04 | 9 | P01584, P62753, P25398, Q9UHA3, P36578, P32969, P18077, P62829, O14786 | IL1B, RPS6, RPS12, RSL24D1, RPL4, RPL9, RPL35A, RPL23, NRP1 | More | | Lorazepam | hsa05202 | Transcriptional misregulation in cancer | 9.99E-05 | 16 | Q12778, Q15532, Q13315, P14780, P27930, Q16548, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, BCL2A1, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, GADD45A | More | | Lorazepam | hsa05212 | Pancreatic cancer | 2.40E-02 | 3 | P31751, Q15311, P23458 | AKT2, RALBP1, JAK1 | More | | Lorazepam | hsa05217 | Basal cell carcinoma | 1.43E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Lorazepam | hsa05231 | Choline metabolism in cancer | 3.38E-02 | 3 | P31751, Q16760, O14986 | AKT2, DGKD, PIP5K1B | More | | Lorazepam | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.73E-05 | 10 | P42338, P19174, P07766, P20963, P09693, P06239, O60603, P10747, Q04759, Q16539 | PIK3CB, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14 | More | | Lorazepam | hsa05321 | Inflammatory bowel disease | 2.80E-06 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | | Lorazepam | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Lorazepam | hsa05330 | Allograft rejection | 1.51E-03 | 2 | P48023, P01375 | FASLG, TNF | More | | Lorazepam | hsa05332 | Graft-versus-host disease | 3.10E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Lorazepam | hsa05415 | Diabetic cardiomyopathy | 1.02E-03 | 8 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D | More | | Lorazepam | hsa05418 | Fluid shear stress and atherosclerosis | 1.08E-03 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |